Bifogade filer
11-20_0331_ZealandPharma_completes subscription
Kurs
+12,09%
Likviditet
88,4 MDKK
Kalender
| Est. tid* | ||
| 2025-11-13 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-14 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-08 | - | Kvartalsrapport 2025-Q1 |
| 2025-03-28 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2025-03-27 | - | Årsstämma |
| 2025-02-20 | - | Bokslutskommuniké 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-21 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2024-03-20 | - | Årsstämma |
| 2024-02-27 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-11 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-30 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2023-03-29 | - | Årsstämma |
| 2023-03-02 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-11 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-09 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2022-04-06 | - | Årsstämma |
| 2022-03-10 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-12 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-16 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2021-04-15 | - | Årsstämma |
| 2021-03-11 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-13 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-03 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2020-04-02 | - | Årsstämma |
| 2020-03-12 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-15 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-05 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2019-04-04 | - | Årsstämma |
| 2019-03-07 | - | Bokslutskommuniké 2018 |
| 2018-11-15 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-16 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-20 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2018-04-19 | - | Årsstämma |
| 2018-03-07 | - | Bokslutskommuniké 2017 |
| 2017-11-08 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-17 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-06 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2017-04-05 | - | Årsstämma |
| 2017-03-15 | - | Bokslutskommuniké 2016 |
| 2016-11-09 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-18 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-20 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2016-04-19 | - | Årsstämma |
| 2016-03-16 | - | Bokslutskommuniké 2015 |
| 2015-11-05 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-28 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-22 | - | Kvartalsrapport 2015-Q1 |
| 2015-04-22 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2015-04-21 | - | Årsstämma |
| 2015-03-12 | - | Bokslutskommuniké 2014 |
| 2014-11-07 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-21 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-06 | - | Kapitalmarknadsdag 2014 |
| 2014-04-29 | - | Årsstämma |
| 2014-04-29 | - | Kvartalsrapport 2014-Q1 |
| 2014-03-21 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2014-03-20 | - | Bokslutskommuniké 2013 |
| 2013-11-15 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-29 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-15 | - | Kvartalsrapport 2013-Q1 |
| 2013-04-30 | - | Årsstämma |
| 2013-04-30 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2013-03-14 | - | Bokslutskommuniké 2012 |
| 2012-11-29 | - | Kapitalmarknadsdag 2012 |
| 2012-04-26 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2012-04-25 | - | Årsstämma |
| 2011-11-17 | - | Kvartalsrapport 2011-Q3 |
| 2011-10-25 | - | Kapitalmarknadsdag 2011 |
| 2011-08-18 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-12 | - | Kvartalsrapport 2011-Q1 |
| 2011-04-29 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2011-04-28 | - | Årsstämma |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Company announcement – No. 11 / 2020
Zealand Pharma completes subscription of New Ordinary Shares and registration of capital increase
Copenhagen, March 31, 2020 – In reference to Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78) company announcement 09/2020 published March 26, 2020, regarding a private placement and directed issue of 741,816 new shares of the company (the "New Ordinary Shares"), Zealand Pharma A/S ("Zealand") announces that it has today increased its share capital by DKK 741,816, divided into 741,816 New Ordinary Shares with a nominal value of DKK 1 each. The gross proceeds from the issuance of the New Ordinary Shares amounts to DKK 137,236,000.
Following the registration of the New Ordinary Shares with the Danish Business Authority, Zealand's share capital amounts to DKK 36,887,952 divided into 36,887,952 shares with a nominal value of DKK 1 each.
The New Ordinary Shares rank pari passu with Zealand's existing shares and carry the same dividend and other rights. Each New Ordinary Share carries one vote at Zealand's general meetings. Zealand only has one class of shares.
The New Ordinary Shares have been issued today and are expected to be admitted to trading on Nasdaq Copenhagen on April 1, 2020 in Zealand's permanent ISIN code DK0060257814.
The amendments to Zealand's articles of association required by the capital increase have been registered today with the Danish Business Authority.
For further information, please contact:
Zealand Pharma Investor Relations
+45 50 60 38 00 investors@zealandpharma.com
Lani Pollworth Morvan, Investor Relations and Communication
lpm@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes clinical license collaboration with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.
Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.